Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 101 - 150 out of 103,585

Document Document Title
WO/2015/032328A1
The present invention relates to an indane derivative, a preparation method therefor, and a pharmaceutical application thereof. Specifically, the present invention relates to a compound shown in formula (I), or a stereoisomer thereof, an...  
WO/2015/032233A1
Disclosed in the present invention is the use of a recombinant Lingzhi mushroom immunomodulatory protein (rLZ_8) expressed by Pichia pastoris in the preparation of drugs for treating focal cerebral ischemia. rLZ_8 is able to treat neurol...  
WO/2015/032519A1
Specific mixtures comprising one or more (cannabinoid) compounds of the formula (A) and/or one or more of the salts thereof are described, as are processes for preparation thereof. Also described are a compound of the formula (A), a salt...  
WO/2015/035167A1
Imidazo[1,2-b]pyridazine-based compounds of the formula: are disclosed, wherein R1, R2 and R3 are defined herein. Compositions comprising the compounds and methods of their use to treat, manage and/or prevent diseases and disorders media...  
WO/2015/034012A1
Provided is a method for manufacturing dopamine-producing neural precursor cells from pluripotent stem cells, the method comprising: (i) a step in which pluripotent stem cells are cultured adherently on an extracellular matrix in a cultu...  
WO/2015/032272A1
The present invention relates to a C-aryl glucoside derivative, a preparation method for same, and medical applications thereof. Specifically, the present invention relates to compounds as represented by formula I, and, tautomers, enanti...  
WO/2015/032966A1
The disclosure relates to thecompound2-(cyclohexylmethyl)-N-{2-[(2S)-1- methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline- 7-sulfonamideor a pharmaceutically acceptable salt thereof, intended forthe treatment of Alzheimer's dis...  
WO/2015/035258A1
In some embodiments, the present invention provides certain compositions and methods that may be useful in the treatment and/or prevention of a neurodevelopmental disorder, such as autism or an autism spectrum disorder (ASD). In some suc...  
WO/2015/027949A1
The present invention relates to the application of a deuterated fumaric acid derivative selected from the following group in the preparation of a drug for the treatment or prevention of multiple sclerosis: 2,3-dideuterio- or 2-deuterio-...  
WO/2015/027296A1
The present specification teaches a protocol for pain management including a pharmaceutical composition and its use in ameliorating the sensation of pain. The protocol comprises the use of a CCL17 signaling antagonist alone or in combina...  
WO/2015/029169A1
Provided is Javanese ginger extract wherein the starting material is Javanese ginger and the desired product is a concentrate (containing solid) obtained from a liquid extract. Treatment by heating or exposure to sunlight is performed du...  
WO/2015/027307A1
The present invention describes benzylthiazolidinone derivatives and pharmaceutical compositions comprising the same; these compounds have shown activity in schizophrenia animal models, with the advantage of not causing the typical adver...  
WO/2015/031722A1
The present invention provides use of an inhibitor of G protein-coupled receptor CXCR4 for treating amyotrophic lateral sclerosis (ALS), for inhibiting glutamate release in astrocytes, or for increasing remyelinization in motor neurons.  
WO/2015/027959A1
The present invention relates to a cyclic peptide compound, and a preparation method, pharmaceutical composition and use thereof. In particular, the cyclic peptide compound of the present invention has a structure as shown by general for...  
WO/2015/027963A1
The present invention relates to an aromatic ring derivative, and pharmaceutical composition and use thereof, in particular to aromatic ring derivatives or hydrates as represented by general formula (II), solvates, stereoisomers thereof,...  
WO/2015/027518A1
Disclosed is a Chinese herbal medicine health-care cigarette, comprising a cigarette stem and a filter tip connected thereto, wherein shredded tobacco is packed inside the cigarette stem and the shredded tobacco is prepared by mixing 10%...  
WO/2015/029968A1
 Provided is a clock gene expression level modifier having extensive history of use as a food, high safety, ready availability, and exceptional processability. A clock gene expression level modifier having as an active ingredient one o...  
WO/2015/031493A1
Methods for treating or preventing a seizure in a subject by administering to the subject a therapeutically effective amount of at least one D-amino acid or D-amino acid oxidase inhibitor are provided. In certain aspects, the method redu...  
WO/2015/028409A1
The invention relates to selective estrogen receptor modulators (SERMs) and to methods for the preparation thereof, to the use thereof for the treatment and/or prophylaxis of disorders, and to the use thereof for producing medicaments fo...  
WO/2015/028673A1
The invention concerns the use of a Cav3, especially Cav3.2, channel blocking agent, ethosuximide in particular, in the treatment or prevention of pain triggered by excess nociception, especially of inflammatory origin. The invention als...  
WO/2015/031392A1
The present invention relates to RNA-based methods for inhibiting the expression of the superoxide dismutase 1 (SOD-1) gene. Recombinant adeno-associated viruses of the invention deliver DNAs encoding RNAs that knock down the expression ...  
WO/2015/028848A1
The present invention provides bicyclic heterocyclic compounds (the compounds of formula I, or an isotopic form, a stereoisomer or a tautomer or a pharmaceutically acceptable salt, a solvate, a polymorph, a prodrug or N-oxide thereof and...  
WO/2015/027342A1
The present application relates to microgel compositions suitable for delivery of substances to the brain. In particular, the present application is directed to microgel compositions comprising a chemically cross-linked microgel and a su...  
WO/2015/028483A1
The present invention relates to compounds of formula I wherein R1 halogen, lower alkyl, lower alkoxy, cyano, phenyl, C(O)NHCH3, C(O)NH2, lower alkyl substituted by halogen or is a five-membered heteroaryl group, optionally substituted b...  
WO/2015/028659A1
The present invention relates to compositions and methods for the treatment of neurological disorders related to glutamate excitotoxicity and Amyloid β toxicity. More specifically, the present invention relates to novel combinatorial th...  
WO/2015/024925A1
The present invention relates to modulators of the unconventional secretory pathway for in the treatment of Alexander disease.  
WO/2015/024819A1
This invention relates to a new medical use for certain chemical compounds and pharmaceutical compositions containing them. The invention relates to compounds which are selective V1a antagonists for use in the treatment of phase shift sl...  
WO/2015/025995A1
Disclosed is a pharmaceutical composition for preventing or treating diseases associated with epilepsy or convulsions, the composition containing a material targeting miR-203. Disclosed are a marker capable of being used for the diagnosi...  
WO/2015/026574A1
The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.  
WO/2015/026170A1
The present invention relates to an indole compound represented by formula (1), a pharmaceutically acceptable salt or isomer thereof, a composition for prevention or treatment of necrosis and necrosis-associated diseases, and a method fo...  
WO/2015/025770A1
Provided is a method for screening a pain inhibitor, characterized by comprising using netrin-4 and/or a netrin-4 receptor and selecting a substance that suppresses the signal transduction downstream of netrin-4. According to the screeni...  
WO/2015/025718A1
The present invention is an adhesive patch which is provided with a supporting body and an adhesive layer that is arranged on at least one surface of the supporting body and is formed of an adhesive composition containing a medical agent...  
WO/2015/025172A1
The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain 5-aryl-thiazol-2-yl-amine compounds of the following formula (I) (for convenience, collectively referred to herein as "5AT2A...  
WO/2015/025980A1
A method for treating neuropathic pain in a mammalian subject, which comprises administering an effective amount of a fatty acid derivative, is provided.  
WO/2015/027146A1
A systematic screening has revealed a family of compounds that exhibit inhibitory effects on 12/15-lipoxygenase. Accordingly, the present invention relates to the use of these compounds for the inhibition of 12/15-lipoxygenase and for th...  
WO/2015/026339A1
This application discloses a composition comprising an amiloride and/or an amiloride analog which can be used for reducing nerve injury or nervous system injury in a subject. The formulation of such composition is also disclosed. The app...  
WO/2015/025323A1
A pharmaceutical composition and method for treating or attenuating a mood or stress-related disorder in a subject having normal or low inflammatory state is provided. In some embodiments, the pharmaceutical composition and method of the...  
WO/2015/025902A1
Provided is a nasal brain function regulator which acts on specific places in a subject's brain using the sense of smell to stimulate or suppress activity of the specific places in the brain, the regulator comprising, as an active ingred...  
WO/2015/023937A1
Provided herein are oligonucleotides that are useful for modulating the heterochromatin state of genes; related compositions and methods are also provided. In some embodiments, methods are provided for treating a disease associated with ...  
WO/2015/023244A1
The invention relates to medicine and to the chemical and pharmaceutical industry, in particular for creating, producing and using cerebro-protective agents for treating and improving blood circulation in the brain. The drug comprises 12...  
WO/2015/023816A1
The present invention is directed to (-)-(2R,3S)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1- yl-propan-1-one (L)-(+) tartrate salt, a pharmaceutical composition comprising said salt, a process for making said salt, and the use of sa...  
WO/2015/023054A1
The present invention relates to an animal model with obsessive compulsive disorder, manufactured by deficiency of Ninjurin 1, and a method for searching candidate drugs for preventing or treating obsessive compulsive disorder using the ...  
WO/2015/023901A1
This disclosure provides isolated cells and compositions comprising one or more isolated cell(s) as described herein. In one aspect, the isolated cell is a pre-term placenta-derived stem cell (also referred to placenta-derived multi pote...  
WO/2015/021943A1
Provided is a method of promoting neurogenesis by administration of an agent that enhance Axin's expression, stability, and/or activity, such as through administration of a tankyrase inhibitor. Further provided are compositions and kits ...  
WO/2015/023289A1
Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, and G are defined herein.  
WO/2015/023142A1
The present invention provides a pharmaceutical composition or a food composition comprising, as active ingredients, flavone-6-C-glucose derivatives or galenical extracts containing flavone-6-C-glucose derivatives. The composition of the...  
WO/2015/021535A1
The disclosure provides methods and uses for alleviating and/or treating pain including pain disorders using melatonin ligands of Formula I: or pharmaceutically acceptable salts thereof wherein: n is 1 or 2; m is 0, 1 or 2; p is 0, 1, 2,...  
WO/2015/022830A1
[Problem] To provide: a composition that is for promoting estrogen secretion and that can promote the secretion of estrogen; an estrogen secretion aromatic composition; and an estrogen aroma tool. [Solution] By means of a method mediated...  
WO/2015/022038A1
Compounds of formula (I) in which R, W, R1, R4, X1, X2, X3, X4 and q have the meanings indicated in Claim 1, are inhibitors of fatty acid synthase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovasc...  
WO/2015/021904A1
Disclosed is a method for synthesizing glatiramer acetate. The present method uses two or multiple depolymerization steps to control the average molecular weight of the glatiramer acetate product within a relatively narrow range.  

Matches 101 - 150 out of 103,585